AXQ Capital’s Caris Life Sciences CAI Stock Holding History

AXQ Capital’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,125	Closed	-$396K	–	1442
2026 Q1	$396K	Buy	22,125 +9,913	+81%	+$217K	0.05%	492
2025 Q4	$329K	Buy	+12,212	New	+$344K	0.07%	407

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHWEPV

J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

SSP

Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AXQ Capital's CAI Position: Q2 2026 in Review

AXQ Capital sold out of Caris Life Sciences (CAI) in Q2 2026, closing a stake of 22,125 shares — an estimated $396K sold.

AXQ Capital first reported a position in CAI in Q4 2025 and held it in 2 quarters. The position peaked at $396K in Q1 2026. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

AXQ Capital reported no remaining Caris Life Sciences position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 22,125 Caris Life Sciences shares in Q2 2026, an estimated $396K.
AXQ Capital first reported a position in Caris Life Sciences in Q4 2025 and held it in 2 quarters.
AXQ Capital's Caris Life Sciences position peaked at $396K in Q1 2026.
246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.